Clinical Trial Update: Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study [Phase 4]

View source ↗

Summary

A Phase 4 pilot trial is evaluating a single-dose PCSK9 inhibitor to improve cardiovascular outcomes after PCI in patients with coronary artery disease. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PCSK9 inhibitor (single-dose)

Snippet

Sponsor: Hanyang University Seoul Hospital | Conditions: Coronary Artery Disease | Phase 4 | Status: NOT_YET_RECRUITING